vimarsana.com
Home
Live Updates
Ciltacabtagene Autoleucel (cilta-cel) Reduced Risk of Disease Progression or Death by 74% vs Standard Regimens for Adult Patients with Relapsed and Refractory Multiple Myeloma in CARTITUDE-4 Study : vimarsana.com
Ciltacabtagene Autoleucel (cilta-cel) Reduced Risk of Disease Progression or Death by 74% vs Standard Regimens for Adult Patients with Relapsed and Refractory Multiple Myeloma in CARTITUDE-4 Study
First analysis data from CARTITUDE-4 demonstrated a statistically significant improvement in progression-free survival, with a hazard ratio of 0.26
CARTITUDE-4 is the first randomized study... | June 5, 2023
Related Keywords
Japan
,
China
,
New Jersey
,
United States
,
American
,
Hemophagocytic Lymphohistiocytosis
,
European Hematology Association
,
Janssen Biotech Inc
,
Medicinal Devices Agency
,
Legend Biotech Corporation
,
American Society Of Clinical Oncology
,
Exchange Commission On
,
Drug Administration
,
Linkedin
,
Community Register Of Orphan Medicinal Products
,
Japan Ministry Of Health
,
American Society Of Oncology Annual Meeting
,
Congress Abstract
,
European Commission
,
Twitter
,
American Cancer Society
,
European Commission For The Treatment Of Patients
,
Legend Biotech
,
New England Journal
,
Hematology Association
,
Hybrid Congress
,
Demonstrated Deep
,
Year Follow Up Data
,
Janssen Biotech
,
Important Safety
,
Release Syndrome
,
Effector Cell Associated Neurotoxicity Syndrome
,
Macrophage Activation Syndrome
,
Risk Evaluation
,
Mitigation Strategy
,
Nerve Palsies
,
Recurrent Cytopenias
,
Igg Hypersensitivity Reactions
,
Use Machines
,
Prescribing Information
,
Boxed Warning
,
Breakthrough Therapy Designation
,
Orphan Drug Designation
,
European Medicines Agency
,
Orphan Medicinal Products
,
Private Securities Litigation Reform Act
,
Annual Report
,
Exchange Commission
,
Oncology Annual Meeting
,
Long Term Remission
,
Refractory Multiple Myeloma After Treatment
,
Year Follow Up
,
Adult Patients
,
Refractory Multiple
,
Accessed October
,
Granted Conditional Approval
,
Receives Approval
,
Community Register
,
Orphan Medicinal
,
Statistics About Multiple Myeloma
,
Accessed January
,
Legend Biotech Corporation Stock Exchange
,
News
,
Information
,
Press Release
,
First
,
Analysis
,
Data
,
Rom
,
Remonstrated
,
Statistically
,
Significant
,
Improvement
,
N
,
Ith
,
Hazard
,
Patio
,
F
,
Us
,
The
,
Andomized Legn Us52490g1022
,
vimarsana.com © 2020. All Rights Reserved.